Routes to enhanced HIV neuropathogenesis through expression of subclinical levels of endogenous amyloid-beta

通过表达亚临床水平的内源性β淀粉样蛋白增强HIV神经发病机制的途径

基本信息

项目摘要

PROJECT SUMMARY We propose a collaborative project between HIV and Alzheimer's Disease (AD) laboratories to investigate potential synergy between HIV infection and amyloid β (Aβ), a key hallmark of aging and AD, in promoting memory impairment. Half of HIV patients on antiretroviral therapy develop neurocognitive impairments (NCI) despite low HIV brain burdens. Age is the most consistent factor affecting NCI progression. We reproduced HIV-NCI pathogenesis in conventional mice infected with EcoHIV, a mouse-tropic HIV. The MPI in the project, Dr. Arancio, reported that non-synaptotoxic doses of exogenous oAβ and Tau, another AD hallmark, cooperate in synaptic dysfunction and memory impairment in mice, suggesting that AD proteins have pathogenic potential at their subclinical concentrations. Our joint preliminary results indicate that similar cooperation occurs after administration of a suboptimal oAβ dose to EcoHIV infected mice or in culture or after EcoHIV infection of cognitively normal APP/PS1 mice, a model of endogenous oAβ accumulation followed by AD pathology. We propose that HIV and subclinical oAβ processes cooperate in disrupting synaptic plasticity to exacerbate HIV- NCI beyond each agent alone. The Specific Aims are to: 1) Define specifics of enhanced HIV-NCI pathogenesis in EcoHIV infected mice accumulating endogenous oAβ prior to showing AD pathology. (A) optimize the onset of memory deficits with EcoHIV infection in preclinical APP/PS1 mice; (B) determine HIV-NCI severity at disease onset by infected oAβ expressing mice for. If aging hAPP-KI mice, a late onset AD model, reproduce findings in APP/PS1 it will be used in subsequent studies. 2) Using a model from Aim 1, we will conduct next generation RNA sequencing (RNA-seq) in infected mice upon reaching HIV disease state compared to controls to: A) generate transcriptome from hippocampus (HPC), prefrontal cortex (PFC), and striatum (STR), and define biological processes specifically associated with memory defects caused jointly by HIV and oAβ; B) confirm some transcripts by RT-QPCR in HPC and STR extracts; and C) conduct limited nuclear-RNA-seq analysis in HPC to assign altered HIV-oAβ processes/transcripts to specific cell types. 3) Study molecular mechanisms responsible for promoting HIV-NCI pathogenesis in the setting of naturally produced subclinical levels of human oAβ in mice. (A) since both HIV and Aβ disturb wnt signaling and cause dendritic pruning, examine how HIV infection of myeloid cells works with Aβ in dysregulating Wnt function in dendritic integrity. B) since EcoHIV downmodulates CaMKII and CREB in mice study potential Aβ-HIV convergence in oAβ dysregulation of the CREB role in synaptic strengthening. Studies will include EcoHIV infection of moderate and late onset AD mice, tests of learning and memory, HPC long-term potentiation HPC synaptodendritic integrity, apoptosis, APP processing, and amyloid pathology system and brain HIV burdens, bioinformatics of mouse brain and select cell types, and use of control non-neuropathogenic EcoHIV∆ Nef.
项目总结

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
CCL2 is required for initiation but not persistence of HIV infection mediated neurocognitive disease in mice.
  • DOI:
    10.1038/s41598-023-33491-7
  • 发表时间:
    2023-04-21
  • 期刊:
  • 影响因子:
    4.6
  • 作者:
    Kim, Boe-Hyun;Hadas, Eran;Kelschenbach, Jennifer;Chao, Wei;Gu, Chao-Jiang;Potash, Mary Jane;Volsky, David J.
  • 通讯作者:
    Volsky, David J.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

OTTAVIO ARANCIO其他文献

OTTAVIO ARANCIO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('OTTAVIO ARANCIO', 18)}}的其他基金

Routes to enhanced HIV neuropathogenesis through expression of subclinical levels of endogenous amyloid-beta
通过表达亚临床水平的内源性β淀粉样蛋白增强HIV神经发病机制的途径
  • 批准号:
    10415699
  • 财政年份:
    2022
  • 资助金额:
    $ 86.85万
  • 项目类别:
Understanding the role of ECSIT in neurodegeneration and Alzheimer's Disease
了解 ECSIT 在神经退行性疾病和阿尔茨海默病中的作用
  • 批准号:
    10629415
  • 财政年份:
    2021
  • 资助金额:
    $ 86.85万
  • 项目类别:
Chaperome networks in Alzheimer's disease
阿尔茨海默病中的伴侣网络
  • 批准号:
    10613466
  • 财政年份:
    2021
  • 资助金额:
    $ 86.85万
  • 项目类别:
Chaperome networks in Alzheimer's disease
阿尔茨海默病中的伴侣网络
  • 批准号:
    10350644
  • 财政年份:
    2021
  • 资助金额:
    $ 86.85万
  • 项目类别:
Understanding the role of ECSIT in neurodegeneration and Alzheimer's Disease
了解 ECSIT 在神经退行性疾病和阿尔茨海默病中的作用
  • 批准号:
    10216433
  • 财政年份:
    2021
  • 资助金额:
    $ 86.85万
  • 项目类别:
Preclinical development of a novel small molecule inhibitor of Alzheimer's disease-related cognitive impairment
阿尔茨海默病相关认知障碍的新型小分子抑制剂的临床前开发
  • 批准号:
    10396647
  • 财政年份:
    2020
  • 资助金额:
    $ 86.85万
  • 项目类别:
Preclinical development of a novel small molecule inhibitor of Alzheimer's disease-related cognitive impairment
阿尔茨海默病相关认知障碍的新型小分子抑制剂的临床前开发
  • 批准号:
    10159812
  • 财政年份:
    2020
  • 资助金额:
    $ 86.85万
  • 项目类别:
Preclinical development of a novel small molecule inhibitor of Alzheimer's disease-related cognitive impairment
阿尔茨海默病相关认知障碍的新型小分子抑制剂的临床前开发
  • 批准号:
    10765513
  • 财政年份:
    2020
  • 资助金额:
    $ 86.85万
  • 项目类别:
Preclinical development of a novel small molecule inhibitor of Alzheimer's disease-related cognitive impairment
阿尔茨海默病相关认知障碍的新型小分子抑制剂的临床前开发
  • 批准号:
    10608172
  • 财政年份:
    2020
  • 资助金额:
    $ 86.85万
  • 项目类别:
The role of SUMOylation in Tau-mediated pathology
SUMO 化在 Tau 介导的病理学中的作用
  • 批准号:
    10083243
  • 财政年份:
    2019
  • 资助金额:
    $ 86.85万
  • 项目类别:

相似国自然基金

靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    0 万元
  • 项目类别:
    面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
  • 批准号:
    2023JJ50274
  • 批准年份:
    2023
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    33 万元
  • 项目类别:
    地区科学基金项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
  • 批准号:
    81973577
  • 批准年份:
    2019
  • 资助金额:
    55.0 万元
  • 项目类别:
    面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
  • 批准号:
    81602908
  • 批准年份:
    2016
  • 资助金额:
    18.0 万元
  • 项目类别:
    青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
  • 批准号:
    81501928
  • 批准年份:
    2015
  • 资助金额:
    18.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

The Phenomenon of Stem Cell Aging according to Methylation Estimates of Age After Hematopoietic Stem Cell Transplantation
根据造血干细胞移植后甲基化年龄估算干细胞衰老现象
  • 批准号:
    23K07844
  • 财政年份:
    2023
  • 资助金额:
    $ 86.85万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Analysis of Age-dependent Functional Changes in Skeletal Muscle CB1 Receptors by an in Vitro Model of Aging-related Muscle Atrophy
通过衰老相关性肌肉萎缩的体外模型分析骨骼肌 CB1 受体的年龄依赖性功能变化
  • 批准号:
    22KJ2960
  • 财政年份:
    2023
  • 资助金额:
    $ 86.85万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Joint U.S.-Japan Measures for Aging and Dementia Derived from the Prevention of Age-Related and Noise-induced Hearing Loss
美日针对预防与年龄相关和噪声引起的听力损失而导致的老龄化和痴呆症联合措施
  • 批准号:
    23KK0156
  • 财政年份:
    2023
  • 资助金额:
    $ 86.85万
  • 项目类别:
    Fund for the Promotion of Joint International Research (International Collaborative Research)
The Effects of Muscle Fatigability on Gait Instability in Aging and Age-Related Falls Risk
肌肉疲劳对衰老步态不稳定性和年龄相关跌倒风险的影响
  • 批准号:
    10677409
  • 财政年份:
    2023
  • 资助金额:
    $ 86.85万
  • 项目类别:
Characterizing gut physiology by age, frailty, and sex: assessing the role of the aging gut in "inflamm-aging"
按年龄、虚弱和性别表征肠道生理学特征:评估衰老肠道在“炎症衰老”中的作用
  • 批准号:
    497927
  • 财政年份:
    2023
  • 资助金额:
    $ 86.85万
  • 项目类别:
Deciphering the role of osteopontin in the aging eye and age-related macular degeneration
破译骨桥蛋白在眼睛老化和年龄相关性黄斑变性中的作用
  • 批准号:
    10679287
  • 财政年份:
    2023
  • 资助金额:
    $ 86.85万
  • 项目类别:
Role of AGE/RAGEsignaling as a driver of pathological aging in the brain
AGE/RAGE信号传导作为大脑病理性衰老驱动因素的作用
  • 批准号:
    10836835
  • 财政年份:
    2023
  • 资助金额:
    $ 86.85万
  • 项目类别:
Elucidation of the protein kinase NLK-mediated aging mechanisms and treatment of age-related diseases
阐明蛋白激酶NLK介导的衰老机制及年龄相关疾病的治疗
  • 批准号:
    23K06378
  • 财政年份:
    2023
  • 资助金额:
    $ 86.85万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Underlying mechanisms of age-related changes in ingestive behaviors: From the perspective of the aging brain and deterioration of the gustatory system.
与年龄相关的摄入行为变化的潜在机制:从大脑老化和味觉系统退化的角度来看。
  • 批准号:
    23K10845
  • 财政年份:
    2023
  • 资助金额:
    $ 86.85万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Targeting Age-Activated Proinflammatory Chemokine Signaling by CCL2/11 to Enhance Skeletal Muscle Regeneration in Aging
通过 CCL2/11 靶向年龄激活的促炎趋化因子信号传导以增强衰老过程中的骨骼肌再生
  • 批准号:
    478877
  • 财政年份:
    2023
  • 资助金额:
    $ 86.85万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了